Today at 9:08 AM ET, Novavax stock rose 32.7% to $105.19 in the pre-market session. The company received $1.6 billion for its COVID-19 vaccine candidate.
AstraZeneca (NYSE:AZN) stock rose 1.4% in pre-market trading at 5:56 AM ET today. Brazil will manufacture AstraZeneca’s experimental coronavirus vaccine.
On March 28, AstraZeneca (AZN) issued a press release announcing its collaboration with Daiichi Sankyo for the development and commercialization of trastuzumab deruxtecan, an investigational therapy currently being evaluated for multiple HER2-expressing cancers.
In the first quarter, Lynparza garnered revenue of $237 million for AstraZeneca (AZN), a YoY (year-over-year) rise of more than 105% driven mainly by its ongoing launch as a second-line maintenance therapy for ovarian cancer and as a therapy for germline BRCA-mutated metastatic breast cancer in the US and Japan.
AstraZeneca’s (AZN) Tagrisso was approved by the FDA first for the treatment of epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer and then as a first-line therapy for EGFR-mutated NSCLC. The drug has become the highest-selling drug in AstraZeneca’s portfolio.
On its first-quarter earnings conference call, AstraZeneca (AZN) guided for year-over-year product sales growth in high-single-digit percentage in 2019. The company, however, expects modest product sales growth in the second half of 2019 due to higher oncology revenue in the previous period.
Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.
In the first quarter, AstraZeneca’s (AZN) Lynparza sales rose 99% YoY (year-over-year) to $237 million on a reported basis, driven by the drug’s rapid uptake in first-line ovarian cancer maintenance and metastatic breast cancer.
In the first quarter, AstraZeneca’s (AZN) Tagrisso sales rose 86% YoY (year-over-year) to $630 million on a reported basis and 92% on a CER (constant exchange rate) basis.
In its first-quarter press release, AstraZeneca (AZN) guided for its fiscal 2019 core operating expenses rising YoY (year-over-year) by a low single-digit percentage.
In its first-quarter press release, AstraZeneca (AZN) reiterated its guidance for high-single-digit percentage growth in its fiscal 2019 product sales.
AstraZeneca (AZN) announced its first-quarter results on April 26. Analysts’ average target price of $46.10 implies a 21.35% upside for AstraZeneca stock.
During AstraZeneca’s fourth-quarter presentation, it highlighted the potential of Tagrisso to become the highest-earning drug in its portfolio in 2019.
In its fourth-quarter earnings press release, AstraZeneca (AZN) guided for a low single-digit YoY (year-over-year) rise in core operating expenses in fiscal 2019.
In its fourth-quarter earnings investor presentation, AstraZeneca (AZN) guided for core EPS of $3.50–$3.70 in fiscal 2019, expecting robust YoY (year-over-year) product sales growth and productivity improvements.
In its fourth-quarter earnings investor presentation, AstraZeneca (AZN) guided for high-single-digit YoY (year-over-year) percentage growth in product sales in fiscal 2019.
In the first nine months of 2018, AstraZeneca (AZN) reported revenues worth $2.85 billion from China, which is a YoY rise of 33% on an actual basis and 27% on a CER (constant exchange rate) basis.
In the first nine months of 2018, AstraZeneca (AZN) reported revenues of $5.12 billion from emerging markets, which is a YoY rise of 13% on an actual basis and 12% on a constant exchange rate (or CER) basis.
In the first nine months of 2018, AstraZeneca reported oncology revenues of $4.26 billion, which is a YoY increase of 47% on an actual basis and 44% on a constant exchange rate (or CER) basis.
As per GlaxoSmithKline’s (GSK) analyst call transcript, Tesaro’s (TSRO) Zejula is competing with AstraZeneca’s (AZN) Lynparza and Clovis Oncology’s (CLVS) Rubraca as maintenance therapy in the second-line platinum-sensitive ovarian cancer indication.
On October 22, 2018, AstraZeneca (AZN) issued a press release announcing positive results from Phase 3 trial SOLO-1, which evaluated PARP inhibitor Lynparza.
Novartis (NVS) missed Wall Street analysts’ estimates for revenues with reported revenues of ~$12.78 billion during the third quarter of 2018, a 2.9% increase in YoY revenues.
Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.
Of the five analysts tracking AstraZeneca in September, three recommended a “strong buy.” One analyst recommended a “buy,” and one analyst recommended a “hold” rating.
Eli Lilly and Company (LLY) reported revenue of ~$6.4 billion in the second quarter, surpassing Wall Street analysts’ estimates for revenue in the period.
On August 27, Johnson & Johnson (JNJ) announced that it has received FDA approval for its combination therapy of Imbruvica and Roche’s (RHHBY) rituximab.
Roche’s (RHHBY) Tecentriq generated revenues of 320.0 million Swiss francs in the first half compared to 237.0 million Swiss francs in the first half of 2017.
This year, analysts expect GlaxoSmithKline’s (GSK) revenue to grow 0.4% YoY (year-over-year) to ~30.3 billion British pounds from ~30.2 billion pounds, and its income margin to narrow YoY to 17.9% from 18.1%.
In the second quarter, GlaxoSmithKline’s (GSK) revenue was nearly flat YoY (year-over-year) at 7.3 billion British pounds, reflecting 4% growth at constant exchange rates offset by a 4% impact by foreign exchange.
